<DOC>
	<DOCNO>NCT00616915</DOCNO>
	<brief_summary>Wellbutrin ( bupropion ) effective antidepressant ( Thase , M 2005 ) . It exist instant release ( IR ) , sustain release ( SR ) extend release ( XL ) form . The IR formulation never approve use Canada . The XL formulation allow daily dose . Wellbutrin norepinephrine dopamine reuptake inhibitor , increase synaptic concentration neurotransmitter . This add positive effect cognition , apathy , tiredness executive functioning . The increased activation may also responsible side effect initial insomnia reduce sleep efficiency , especially take night .</brief_summary>
	<brief_title>Does Sleep Quality Change After Switch From Wellbutrin SR Wellbutrin XL Patients With Major Depressive Disorder ?</brief_title>
	<detailed_description>Wellbutrin SR formulation give 150 mg single dose high dos commonly require treatment depression ; also give least 8 hour apart order avoid peak plasma concentration reduce risk seizure ( incidence 0.1 % dos Â£ 300 mg ) . The twice day dose may result complaint insomnia may necessitate discontinue medication add sleep promoting agent . The benefit once-daily dosing understate give treatment adherence typically low depressed patient non-depressed counterpart ; , 8 h dose interval bupropion SR likely low adherence compare traditional bid dosing ( i.e. , morning evening ) ; thus , difficult imagine patient miss 30-50 % second dose give difficulty recall take second dose work school . The review Fava et al . ( 2005 ) plot relative PK profile XL SR note significantly low bupropion concentration bedtime , likely reduce occurrence insomnia . Therefore , Wellbutrin XL may improve adherence eliminate second dose Wellbutrin XL also avoids high plasma drug concentration bedtime , see bupropion SR , associate insomnia . Further , smoother pharmacokinetic profile Wellbutrin XL may improve overall tolerability compare Wellbutrin SR .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>1 . Signed Patient Informed Consent ; 2 . Patients Major Depressive Disorders ( DSMIVTR criterion use ) ; 3 . Outpatients ; 4 . Males females 18 year age ; 5 . Patients currently use Wellbutrin SR. 1 . Bipolar Disorder patient ; 2 . Actively suicidal patient ; 3 . Schizophrenia , Schizoaffective Psychotic Disorder ; 4 . Pregnant woman , pregnancy test beginning study ; 5 . Women childbearing age , refuse use appropriate contraception , breastfeed mother ; 6 . Patients know hypersensitivity bupropion ; 7 . Patients severe unstable medical condition , opinion investigator would interfere progress safety ; 8 . ECT TMS treatment within last three month ; 9 . Patients respond previous treatment bupropion ; 10 . Patients history seizure disorder ; 11 . Patients history eat disorder ( e.g . bulimia , anorexia nervosa ) ; 12 . Patients use sleep aid medication ( Benzodiazepines , barbiturates ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Wellbutrin SR</keyword>
</DOC>